Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis E. Bemis who wrote (119)	3/25/1999 6:56:00 PM
From: Curtis E. Bemis	Read Replies (1) \| Respond to of 395

Answered my own question-- RGEN and 8K-- Purchase of Secretin rights From 8K (summary) Item 2. Acquisition or Disposition of Assets. - ---------------------------------------------- On March 9, 1999, Repligen Corporation, Inc. (the "Company") acquired all rights to certain patent applications relating to the use of secretin in the prevention or treatment of autism. The rights were acquired from the joint owners, Victoria A. Beck, a United States resident ("Beck"), and Autism Research Institute, a not-for-profit organization incorporated in the State of California ("ARI") pursuant to a Patent Purchase Agreement by and among the Company, Beck and ARI, dated as of March 9, 1999 (the "Purchase Agreement"). At the closing, the Company paid $150,000 in cash, and issued a warrant exercisable for up to 350,000 shares of common stock of the Company with an exercise price of $1.59 per share, and issued 262,500 shares of common stock of the Company. In addition, the Company has agreed to make certain milestone payments to Beck and ARI (a) upon the Company's filing of a new drug application with the United States Food and Drug Administration ("FDA") for a clinical indication covered by the intellectual property rights transferred by the Purchase Agreement and (b) upon the approval by the FDA of a product covered by the intellectual property rights transferred to the Company pursuant to the Purchase Agreement. Finally, the Company has also agreed to pay certain royalty payments to Beck and ARI in the event the Company is able to derive sales and/or license revenues from the intellectual property rights acquired from Beck and ARI pursuant to the Purchase Agreement. The source of the funds used in this acquisition was the Company's working capital. The purchase price and terms for the transaction were determined in arm's length negotiations.